---
title: "Reviva Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286315254.md"
datetime: "2026-05-13T20:44:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286315254.md)
  - [en](https://longbridge.com/en/news/286315254.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286315254.md)
---

# Reviva Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.46.

EBIT: As of FY2026 Q1, the actual value is USD -3.355 M.

#### Financial Performance

Reviva Pharmaceuticals Holdings, Inc. reported a net loss of - $3,195,987 for the three months ended March 31, 2026, an improvement compared to a net loss of - $6,432,840 for the same period in 2025. The net loss per share for Q1 2026 was - $0.46, compared to - $2.61 per share for Q1 2025.

#### Operating Expenses

Total operating expenses for the three months ended March 31, 2026, were $3,271,952, a decrease from $6,538,167 in the prior year period. Research and development expenses decreased to $1,435,135 in Q1 2026 from $4,113,537 in Q1 2025. General and administrative expenses were $1,836,817 in Q1 2026, down from $2,424,630 in Q1 2025.

#### Loss from Operations

Loss from operations for Q1 2026 was - $3,271,952, an improvement from - $6,538,167 in Q1 2025.

#### Other Income (Expense)

Total other income, net, was $79,311 for Q1 2026, compared to $110,540 for Q1 2025. This included interest income of $89,354 in Q1 2026, slightly up from $86,111 in Q1 2025. Interest expense was - $6,653 in Q1 2026 and - $11,620 in Q1 2025.

#### Cash and Cash Equivalents

As of March 31, 2026, cash and cash equivalents totaled $22,190,231, an increase from $14,438,792 as of December 31, 2025.

#### Total Assets and Liabilities

Total assets amounted to $23,559,636 as of March 31, 2026, up from $15,923,198 as of December 31, 2025. Total liabilities decreased to $6,119,155 as of March 31, 2026, from $7,275,553 as of December 31, 2025.

#### Stockholders’ Equity

Total stockholders’ equity was $17,440,481 as of March 31, 2026, an increase from $8,647,645 as of December 31, 2025.

#### Operational Highlights

Reviva Pharmaceuticals Holdings, Inc. filed a U.S. composition of matter provisional patent application for a new form of brilaroxazine, potentially extending patent life and commercial exclusivity through 2046. The company completed a public equity offering in March 2026, raising gross proceeds of $10.0 million. Clinical vocal biomarker data from the RECOVER Phase 3 trial was published in _Biological Psychiatry_, and the company’s common stock will transition from Nasdaq to OTCQB Venture Market quotation on May 14, 2026.

#### Business Outlook

Reviva Pharmaceuticals Holdings, Inc. expects to initiate patient enrollment in the RECOVER-2 Phase 3 trial in Q3 2026. FDA feedback on the use of a new form of brilaroxazine in the RECOVER-2 trial and future New Drug Application (NDA) is anticipated in mid-2026. The company also plans additional publications on brilaroxazine for schizophrenia in 2026 and is pursuing partnership opportunities for its pipeline.

### Related Stocks

- [RVPH.US](https://longbridge.com/en/quote/RVPH.US.md)

## Related News & Research

- [Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | RVPH Stock News](https://longbridge.com/en/news/286313938.md)
- [Reviva Pharmaceuticals Q1 net loss narrows on lower expenses](https://longbridge.com/en/news/286314912.md)
- [Reviva Pharma Prices $10 Mln Public Offering Of Shares And Series G And H Warrants; Stock Down](https://longbridge.com/en/news/279731611.md)
- [FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug](https://longbridge.com/en/news/270629724.md)
- [Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital](https://longbridge.com/en/news/270623164.md)